ClinicalTrials.gg
CompletedNCT06699329Updated Nov 21, 2024

A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)

A Phase 1 interventional study of Enlicitide Decanoate and Semaglutide in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2024, 2 years 5 months ago, and no results have been posted to the registry.
  • Registered 9 months after the study started (first participant enrolled Jan 2024, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Semaglutide is a drug used to treat type 2 diabetes.

Researchers want to learn what happens to the amount of semaglutide and enlicitide decanoate in a person's blood when each drug is taken alone and when they are taken together.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
  • Medically healthy with no medical history

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • History of gastrointestinal disease which may affect food and drug absorption, or has had a gastric bypass or similar surgery
  • History of cancer
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Enlicitide Decanoate and Semaglutide

    Period 1: Participants receive an oral dose of enlicitide decanoate every day for 1 week. Period 2: Participants receive an oral dose of semaglutide every day for 6 weeks. Period 3: Participants receive an oral dose of both enlicitide decanoate and semaglutide every day for 1 week.

    Drug: Enlicitide Decanoate · Drug: Semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Enlicitide Decanoate

    Blood samples will be collected to determine the AUC0-24hrs of enlicitide decanoate.

    Time frame: At designated timepoints (up to 24 hours postdose)

  2. Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hrs) of Semaglutide

    Blood samples will be collected to determine the AUC0-24hrs of semaglutide.

    Time frame: At designated timepoints (up to 24 hours postdose)

  3. Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate

    Blood samples will be collected to determine the Cmax of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  4. Maximum Plasma Concentration (Cmax) of Semaglutide

    Blood samples will be collected to determine the Cmax of semaglutide.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  5. Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate

    Blood samples will be collected to determine the Tmax of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

  6. Time to Maximum Plasma Concentration (Tmax) of Semaglutide

    Blood samples will be collected to determine the Tmax of semaglutide.

    Time frame: At designated timepoints (up to approximately 2 weeks postdose)

Secondary outcomes

  1. Number of Participants Who Experience a Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE will be considered treatment-emergent if the onset date and time is at the time of or after first study drug administration. The number of participants who experience a TEAE will be reported.

    Time frame: Up to approximately 12 weeks

  2. Number of Participants Who Discontinue Study Due to a TEAE

    An adverse event (AE) means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE will be considered treatment-emergent if the onset date and time is at the time of or after first study drug administration. The number of participants who discontinue study due to a TEAE will be reported.

    Time frame: Up to approximately 12 weeks

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in May 2024, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 21, 2024
StartActual
Jan 22, 2024
Primary completionActual
May 24, 2024
CompletionActual
May 24, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06699329
Responsible party
Sponsor
First posted
Nov 21, 2024
Start date
Jan 22, 2024
Primary completion
May 24, 2024
Completion
May 24, 2024
Last update
Nov 21, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-0616

Start the discussion